View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 21, 2022

OliPass begins dosing in Phase IIa trial of painkiller for osteoarthritis

The biotech firm received approval from the Australian regulatory authority for the trial in October last year.

OliPass Corporation has initiated the dosing of the subjects in Phase IIa clinical trial of painkiller OLP-1002 for osteoarthritis patients with pain. 

The trial will have a two-stage adaptive design.

The initial stage is an open-label trial to detect the optimal dose range for the efficacy profile. 

Subjects enrolled in this stage of the trial will be given one subcutaneous dose of OLP-1002 ranging between 1mcg and 80mcg

The placebo-controlled, double-blind second stage of the trial will analyse two doses of the pain killer chosen as per the data from the first stage. 

In October last year, the South Korea-based biotech firm obtained approval from the Australian regulatory authority for the trial.

OliPass Corporation CEO Dr Shin Chung said: “OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy. 

“Early readouts from the ongoing Phase IIa trial are consistent with our expectations for OLP-1002 as a selective inhibitor of the Nav1.7 sodium channel. 

“Even though the early readouts may look very promising, the therapeutic profile of OLP-1002 has yet to be validated by a placebo-controlled evaluation in a larger number of patients.”

OliPass focuses on developing Ribonucleic acid (RNA) treatments leveraging Olipass Peptide Nucleic Acid (OPNA), its oligonucleotide platform.

OPNA was obtained by making chemical alterations to PNA to boost cell permeability, as well as RNA affinity. 

It is claimed to attach to target pre-mRNA, elicits exon skipping and results in mRNA splice variant for treatment intervention. 

As against various other kinds of RNA treatments, OPNA does not need formulation support for in vivo therapeutic activity.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy